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 Side chain theory of immunity
 Antibodies - magic bullets 1899/1906
Therapy of Non Hodgkin’s Lymphoma (NHL) 
Bexxar ®
Tositumomab labeled with I-131
Zevalin ®
Ibritumomab tiuxetan labeled with Y-90
Are antibodies really “magic bullets”?
Therapy of Non Hodgkin lymphoma (NHL)




 NHL is sensitive to radiation
 can be curative in early stage NHL
















































Half-life 64 hours 8.04 days 6.71 days
Mean path-
length














































Radiolabeling of kits &
physicochemical evaluation
 reconstitution in 0.9% NaCl, in the presence of acetate 
ions at pH 7.0 with Lutetium-177 with specific activity of 





Radiolabeling with 177Lu after reconstitution of lyophilisates
SE – HPLC / ITLC 
 High radiochemical purity
Conclusion
 Lyophilized kits, ready to label with 177Lu
 Candidates for pre-clinical cell and animal studies
 Candidates for new ready to label rituximab for NHL 
therapy
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